By first targeting T-cell lymphoma, Corvus gathers crucial safety and biologic effect data in humans. This knowledge about the drug's impact on T-cells directly informs and de-risks subsequent trials in autoimmune diseases like atopic dermatitis, creating a capital-efficient development path.

While targeting intracellular peptide-MHC complexes opens the entire proteome as potential cancer targets, the approach is limited by HLA restriction. This means a drug might only be applicable to 30-40% of patients, a major commercial and clinical drawback that complicates development despite the potential for exquisite specificity.

Companies like VIR are making progress with masked T-cell engagers that limit systemic toxicity like cytokine release syndrome (CRS). This approach, which concentrates efficacy at the tumor site, could be the key to unlocking the broad potential of T-cell engagers beyond hematologic malignancies into the much larger solid tumor market.

T-cell engagers (TCEs) are likely to be safer in autoimmune conditions than in cancer. Autoimmune patients have a relatively normal B-cell count, unlike the massive proliferation in hematologic cancers. This lower target cell burden naturally limits the scale of T-cell activation and inflammatory toxicity.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

While some firms repurpose cancer T-cell engagers (TCEs), a new wave of innovation is emerging from China. These biotechs are designing novel, "fit-for-purpose" constructs like trispecifics and molecules with co-stimulatory receptors specifically for the unique safety and efficacy demands of autoimmune disease.

While peptide-MHC targeting can theoretically apply to modalities like antibody-drug conjugates (ADCs), the commercial and safety value proposition is vastly superior in T-cell engagers. ADCs can tolerate low residual target expression on healthy tissue, but the extreme potency of T-cell engagers requires strictly tumor-exclusive targets to avoid toxicities, making intracellular pMHC targets uniquely suited to engagers.

Immuneering selected pancreatic cancer not just for the unmet need, but because 97% of cases are driven by the MAPK pathway. This homogeneity means patients can enroll in trials without prior genetic testing, removing a significant bottleneck and speeding up the clinical development timeline.

For solid tumors, the critical design hurdle for T-cell engagers is achieving selectivity. Most target antigens are also expressed at low levels on healthy cells, so molecules must be engineered to attack tumors with high antigen expression while sparing healthy tissue to avoid on-target, off-tumor toxicity.